Digestive Disease Week 2020 (DDW 2020)

Chicago, Illinois, US 02 May 2020 - 05 May 2020

Vonoprazan tops lansoprazole in reducing erosive oesophagitis recurrence in Asians

19 Jun 2020 by

A once-daily maintenance dose of vonoprazan 10 mg or 20 mg may be a suitable substitute to lansoprazole in reducing the risk of erosive oesophagitis (EE) recurrence, according to a phase III noninferiority study presented at DDW 2020.

Vonoprazan tops lansoprazole in reducing erosive oesophagitis recurrence in Asians

19 Jun 2020

Too much or too little sleep triggers constipation

17 Jun 2020 by

Too much or too little sleep triggers constipation in a study of nearly 15,000 adults.

Too much or too little sleep triggers constipation

17 Jun 2020

Regular aspirin use may reduce GI cancer risk

16 Jun 2020 by

Regular use of aspirin may reduce the risk of gastrointestinal cancers, according to two studies presented at DDW 2020.

Regular aspirin use may reduce GI cancer risk

16 Jun 2020

Plecanatide favourable for older individuals with CIC, IBS-C

16 Jun 2020 by

The guanylate cyclase-C receptor agonist plecanatide is effective and well-tolerated by older individuals (≥65 years) with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), results of a post hoc analysis presented at DDW 2020 has shown.

Plecanatide favourable for older individuals with CIC, IBS-C

16 Jun 2020

Rifaximin effective in treatment unresponsive IBS-D

15 Jun 2020 by

Patients with irritable bowel syndrome with diarrhoea (IBS-D) who have not responded to other medications may benefit from rifaximin, post hoc analyses of the TARGET 3* trial showed.

Rifaximin effective in treatment unresponsive IBS-D

15 Jun 2020

SC vedolizumab improves outcomes in patients with Crohn’s disease

12 Jun 2020 by

Maintenance therapy with a new subcutaneous (SC) formulation of the monoclonal antibody vedolizumab led to improvements in patient-reported outcomes (PROs) in patients with moderate-to-severe active Crohn’s disease (CD) compared with placebo, interim results of the phase III VISIBLE 2 study has shown.

SC vedolizumab improves outcomes in patients with Crohn’s disease

12 Jun 2020

Budesonide oral suspension improves endoscopic outcomes in eosinophilic oesophagitis

08 Jun 2020 by

Budesonide oral suspension (BOS), a liquid formulation of a topical corticosteroid, improved endoscopic outcomes in patients with eosinophilic oesophagitis (EoE), a phase III trial has shown.

Budesonide oral suspension improves endoscopic outcomes in eosinophilic oesophagitis

08 Jun 2020